Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
Executive Summary Orforglipron (LY3502970) is the first oral, non-peptide, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist to complete Phase 3 clinical development for the treatment of obesity and type 2 diabetes
Creatine monohydrate has an extensive safety record and no known interaction with GLP-1 medications
Beyond metabolic disease, these multifunctional agonists have the potential to treat diseases where targeted medicinal action is preferred over systematic administration, as demonstrated with the GLP-1/oestrogen conjugate
It would be possible to synthesize them chemically, which would be a cost-effective cancer treatment [19,20,21]
Ipamorelin avoids this problem almost entirely
US$ 24.08
US$ 28.23
US$ 28.40
US$ 25.42
